Community News

Due diligence to guide venture capital investment

December 8, 2021

The multi-institutional project team will perform due diligence on life science and therapeutics startups under consideration by venture capital firms in the Bay Area. For each company, the team may evaluate the following key areas: 1) company capabilities (e.g. scientific merit, intellectual property, etc.), 2) market attractiveness, and 3) competitive landscape. Team members will interact […]

Read More

Indication prioritization for a therapeutics company targeting aging diseases

December 8, 2021

As advances in medicine and technology have enabled societies to enjoy longer lifespans, increasing numbers of people will live to experience the negative effects age-associated diseases. An early-stage therapeutics company has engaged BCBA to identify appropriate molecular targets to combat age-associated diseases using high-throughput, high-dimensional approaches. Specifically, the BCBA team will use primary and secondary […]

Read More

Market opportunity assessment for a molecular structure determination platform company

October 21, 2021

An early-stage contract research organization (CRO) is providing high-throughput molecular structure determination services using a cutting-edge platform, enabling them to determine structures cheaper and more quickly than many competitors. The company believes that these advantages will enable them to capture a significant proportion of the molecular structure determination market, and that a large market opportunity […]

Read More

GPCR targets for an antibody therapeutics company

September 11, 2021

An early-stage biotechnology company with expertise in antibody therapeutics development is engaging BCBA to explore the GPCR-targeted therapeutics market. To that end, the BCBA project team will 1) conduct a comprehensive market landscape analysis of the GPCR therapeutic market to understand the market conditions and requirements for the development of compelling Proof-of-Concept (POC) programs in […]

Read More

Due diligence to guide venture capital investment

August 27, 2021

The multi-institutional project team will perform due diligence on life science and therapeutics startups under consideration by venture capital firms in the Bay Area. For each company, the team may evaluate the following key areas: 1) company capabilities (e.g. scientific merit, intellectual property, etc.), 2) market attractiveness, and 3) competitive landscape. Team members will interact […]

Read More

Strategic planning to increase awareness and adoption of Far-UVC light technology

June 12, 2021

An early-stage product company is developing smart solutions for whole-room health. The company has developed a light that emits in the far-UVC range, which has been shown to kill many pathogens and strongly indicated to be completely harmless to humans. This technology has the potential to revolutionize public health and greatly reduce the transmission of […]

Read More

Optimization of a direct-to-consumer test for the assessment of chronic inflammation

March 26, 2021

A direct-to-consumer (DTC) diagnostics company is developing a blood test panel for the assessment of chronic inflammation. Using a cutting-edge AI-based platform, the company is optimizing a panel that can provide their customers with deep insights on their inflammatory status with only a few drops of blood. Given the massive increase in DTC and telemedicine […]

Read More

Application prioritization for a next-generation antibody design and characterization platform

March 12, 2021

An early stage protein therapeutics company has developed a novel AI-driven platform for rapid, iterative antibody design and characterization and is in the process of prioritizing applications of their platform for a set of initial Proof of Concept (POC) programs. To that end, the BCBA project team will 1) evaluate the current research and framework […]

Read More

Market opportunity assessment for a high-throughput biologic manufacturing platform

February 19, 2021

An early-stage, global health focused platform company has developed methods to rapidly generate a variety of biologics inexpensively and in high throughput. The company is interested in understanding how to best position themselves in the market based on the competitive advantages that their platform provides. In particular, the company believes that the flexibility and rapid […]

Read More

Market opportunity assessment of novel bispecific antibodies for immuno-oncology

September 25, 2020

An early-stage therapeutics company is developing novel T-cell-engaging bispecific antibodies that enable targeted stimulation of the immune system to kill tumor cells.

Read More